Paul Andrew Antony

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
    Paul Andrew Antony
    Surgery Branch, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:202-6. 2002
  2. pmc CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2
    Paul Andrew Antony
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892, USA
    J Immunother 28:120-8. 2005

Collaborators

Detail Information

Publications2

  1. pmc Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
    Paul Andrew Antony
    Surgery Branch, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:202-6. 2002
    ..The challenge for immunotherapists now is to overcome immunosuppression using the knowledge gained through the understanding of T regulatory cell function...
  2. pmc CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2
    Paul Andrew Antony
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892, USA
    J Immunother 28:120-8. 2005
    ..The authors propose that other gamma c-signaling cytokines, including IL-15, may be alternative choices for the immunotherapy of cancer...